Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan;5(1):30-43.
doi: 10.1177/2040622313511286.

Glaucoma management: relative value and place in therapy of available drug treatments

Deepak Sambhara  1 , Ahmad A Aref  2
Affiliations
Review

Glaucoma management: relative value and place in therapy of available drug treatments

Deepak Sambhara et al. Ther Adv Chronic Dis. 2014 Jan.

Abstract

Lowering intraocular pressure (IOP) is the only proven therapeutic intervention for glaucomatous optic neuropathy. Despite advances in laser and microsurgical techniques, medical IOP reduction remains the first-line treatment option for the majority of patients with open-angle glaucoma. Prostaglandin analogs are the most efficacious topical agents and carry a remarkable safety profile. Topical beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors are often employed as adjunctive agents for further IOP control. Newer preserved and nonpreserved formulations are available and appear to be less toxic to the ocular surface. Oral carbonic anhydrase inhibitors, miotic agents, and hyperosmotics are infrequently used due to a host of potentially serious adverse events. Medical therapies on the horizon include rho-kinase inhibitors, neuroprotective interventions, and gene therapies.

Keywords: anterior chamber; glaucoma; ocular hypertension; ophthalmic solutions; optic nerve diseases; trabecular meshwork; vision disorders.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Dr Aref has served as a paid speaker for Alcon Laboratories Inc. and Merck Sharp & Dohme, Inc. Mr Sambhara has no conflicts of interest to declare.

References

    1. AAO (2003) Preferred Practice Patterns in the Management of Glaucoma and Ocular Hypertension. San Francisco, CA: AAO Press
    1. AGIS Investigators (2000) The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130: 429–440 - PubMed
    1. Aihara M., Oshima H., Araie M. EXTraKT Study Group (2013) Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface - a multicentre randomized single-masked study. Acta Ophthalmol 91(1): e7–e14 - PubMed
    1. Alm A., Grierson I., Shields M. (2008) Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 53(Suppl. 1): S93–S105 - PubMed
    1. Alqawlaq S., Huzil J., Ivanova M., Foldvari M. (2012) Challenges in neuroprotective nanomedicine development: progress towards noninvasive gene therapy of glaucoma. Nanomedicine (Lond) 7: 1067–1083 - PubMed